Medtronic PLC (NYSE:MDT) is set to report its fiscal fourth quarter 2026 results before the opening bell on Wednesday, June 3.
Analysts expect the Minneapolis, Minnesota-based company to post revenue of $9.61 billion, up 7.6% from the year-ago quarter, and EPS of $1.55, representing a 4.3% decline from the $1.62 reported for the same quarter last year.
Medtronic has entered into an agreement to buy SPR Therapeutics, a manufacturer of peripheral nerve stimulation devices to treat chronic pain, for $650 million in cash. The acquisition will mark Medtronic's third major purchase in 2026 and add to the company's neuromodulation business.
Medtronic shares rose 0.31% to close at $73.75 on Tuesday.
Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
